Background: 1% of all cancers and about 10% of all haematologic malignancies are multiple myeloma (MM). In various human cancers, including multiple myeloma, abnormal expression or deregulation of JAM-A, which controls cell growth and differentiation, results in a more aggressive phenotype and poor prognosis. Aim: to evaluate the immunohistochemical expression of JAM-A in cases of multiple myeloma and correlate its expression with variable clinicopathological parameters to assess its possible diagnostic and prognostic role and hence therapeutic modalities. Material and method: This is a selected retrospective immunohistochemical study of JAM-A performed on 40 cases of MM.